123 related articles for article (PubMed ID: 33214693)
1. TP53 alterations of hormone-naïve prostate cancer in the Chinese population.
Liu Z; Guo H; Zhu Y; Xia Y; Cui J; Shi K; Fan Y; Shi B; Chen S
Prostate Cancer Prostatic Dis; 2021 Jun; 24(2):482-491. PubMed ID: 33214693
[TBL] [Abstract][Full Text] [Related]
2. Inter-tumor genomic heterogeneity of breast cancers: comprehensive genomic profile of primary early breast cancers and relapses.
Fumagalli C; Ranghiero A; Gandini S; Corso F; Taormina S; De Camilli E; Rappa A; Vacirca D; Viale G; Guerini-Rocco E; Barberis M
Breast Cancer Res; 2020 Oct; 22(1):107. PubMed ID: 33059724
[TBL] [Abstract][Full Text] [Related]
3. Clinically significant genomic alterations in the Chinese and Western patients with intrahepatic cholangiocarcinoma.
Xu S; Guo Y; Zeng Y; Song Z; Zhu X; Fan N; Zhang Z; Ren G; Zang Y; Rao W
BMC Cancer; 2021 Feb; 21(1):152. PubMed ID: 33579226
[TBL] [Abstract][Full Text] [Related]
4. Whole Slide Imaging-Based Prediction of TP53 Mutations Identifies an Aggressive Disease Phenotype in Prostate Cancer.
Pizurica M; Larmuseau M; Van der Eecken K; de Schaetzen van Brienen L; Carrillo-Perez F; Isphording S; Lumen N; Van Dorpe J; Ost P; Verbeke S; Gevaert O; Marchal K
Cancer Res; 2023 Sep; 83(17):2970-2984. PubMed ID: 37352385
[TBL] [Abstract][Full Text] [Related]
5. Identification of recurrent BRAF non-V600 mutations in intraductal carcinoma of the prostate in Chinese populations.
Hu J; Chen X; Sun F; Liu L; Liu L; Yang Z; Zhang H; Yu Z; Zhao R; Wang Y; Liu H; Yang X; Sun F; Han B
Neoplasia; 2024 Apr; 50():100983. PubMed ID: 38417222
[TBL] [Abstract][Full Text] [Related]
6. Pan-cancer Analysis of CDK12 Alterations Identifies a Subset of Prostate Cancers with Distinct Genomic and Clinical Characteristics.
Nguyen B; Mota JM; Nandakumar S; Stopsack KH; Weg E; Rathkopf D; Morris MJ; Scher HI; Kantoff PW; Gopalan A; Zamarin D; Solit DB; Schultz N; Abida W
Eur Urol; 2020 Nov; 78(5):671-679. PubMed ID: 32317181
[TBL] [Abstract][Full Text] [Related]
7. The impact of telomere length on prostate cancer aggressiveness, genomic instability and health disparities.
Huang R; Bornman MSR; Stricker PD; Simoni Brum I; Mutambirwa SBA; Jaratlerdsiri W; Hayes VM
Sci Rep; 2024 Apr; 14(1):7706. PubMed ID: 38565642
[TBL] [Abstract][Full Text] [Related]
8. Pan-Cancer Analysis of
Sokol ES; Pavlick D; Frampton GM; Ross JS; Miller VA; Ali SM; Lotan TL; Pardoll DM; Chung JH; Antonarakis ES
Oncologist; 2019 Dec; 24(12):1526-1533. PubMed ID: 31292271
[TBL] [Abstract][Full Text] [Related]
9. Tumour-based Mutational Profiles Predict Visceral Metastasis Outcome and Early Death in Prostate Cancer Patients.
Cussenot O; Timms KM; Perrot E; Blanchet P; Brureau L; Solimeno C; Fromont G; Comperat E; Cancel-Tassin G
Eur Urol Oncol; 2024 Jan; ():. PubMed ID: 38182487
[TBL] [Abstract][Full Text] [Related]
10. Using Machine Learning to Predict TP53 Mutation Status and Aggressiveness of Prostate Cancer from Routine Histology Images.
Bordeleau F
Cancer Res; 2023 Sep; 83(17):2809-2810. PubMed ID: 37655432
[TBL] [Abstract][Full Text] [Related]
11. Clinical Outcomes of TP53 Mutations in Cancers.
Robles AI; Jen J; Harris CC
Cold Spring Harb Perspect Med; 2016 Sep; 6(9):. PubMed ID: 27449973
[TBL] [Abstract][Full Text] [Related]
12. Prospective clinical sequencing of 1016 Chinese prostate cancer patients: uncovering genomic characterization and race disparity.
Wei Y; Zhang T; Wang B; Pan J; Jin S; Fang B; Gu W; Qin X; Dai B; Lin G; Gan H; Wu J; Ye D; Zhu Y
Mol Oncol; 2023 Oct; 17(10):2183-2199. PubMed ID: 37584393
[TBL] [Abstract][Full Text] [Related]
13. Genomic profile of Chinese patients with endometrial carcinoma.
Li J; Li X; Quan C; Li X; Wan C; Wu X
BMC Cancer; 2023 Sep; 23(1):888. PubMed ID: 37730563
[TBL] [Abstract][Full Text] [Related]
14. Loss of heterozygosity impacts MHC expression on the immune microenvironment in CDK12-mutated prostate cancer.
Lautert-Dutra W; M Melo C; Chaves LP; Crozier C; P Saggioro F; B Dos Reis R; Bayani J; Bonatto SL; Squire JA
Mol Cytogenet; 2024 May; 17(1):11. PubMed ID: 38704603
[TBL] [Abstract][Full Text] [Related]
15. Prevalence of mutations in common tumour types in Northern England and comparable utility of national and international Trial Finders.
Rae S; Plummer E; Fitzgerald L; Hogarth L; Bridgewood A; Brown-Schofield L; Graham J; Haigh S; McAnulty C; Drew Y; Haris N; Bashir S; Plummer R; Greystoke A
J Cancer Res Clin Oncol; 2023 Dec; 149(18):16355-16363. PubMed ID: 37702806
[TBL] [Abstract][Full Text] [Related]
16. The Impact of Whole Genome Data on Therapeutic Decision-Making in Metastatic Prostate Cancer: A Retrospective Analysis.
Crumbaker M; Chan EKF; Gong T; Corcoran N; Jaratlerdsiri W; Lyons RJ; Haynes AM; Kulidjian AA; Kalsbeek AMF; Petersen DC; Stricker PD; Jamieson CAM; Croucher PI; Hovens CM; Joshua AM; Hayes VM
Cancers (Basel); 2020 May; 12(5):. PubMed ID: 32392735
[TBL] [Abstract][Full Text] [Related]
17. The prevalence and clinical implication of rare germline deleterious alterations in Chinese patients with prostate cancer: A real-world multicenter study.
Fei X; Fan L; Chen W; Chen W; Gong Y; Du X; Wang Y; Zhu Y; Pan J; Wang F; Zhao W; Liu T; Yang Y; Dong B; Xue W
Clin Transl Med; 2021 Oct; 11(10):e527. PubMed ID: 34709755
[No Abstract] [Full Text] [Related]
18. OncoKB: A Precision Oncology Knowledge Base.
Chakravarty D; Gao J; Phillips SM; Kundra R; Zhang H; Wang J; Rudolph JE; Yaeger R; Soumerai T; Nissan MH; Chang MT; Chandarlapaty S; Traina TA; Paik PK; Ho AL; Hantash FM; Grupe A; Baxi SS; Callahan MK; Snyder A; Chi P; Danila D; Gounder M; Harding JJ; Hellmann MD; Iyer G; Janjigian Y; Kaley T; Levine DA; Lowery M; Omuro A; Postow MA; Rathkopf D; Shoushtari AN; Shukla N; Voss M; Paraiso E; Zehir A; Berger MF; Taylor BS; Saltz LB; Riely GJ; Ladanyi M; Hyman DM; Baselga J; Sabbatini P; Solit DB; Schultz N
JCO Precis Oncol; 2017 Jul; 2017():. PubMed ID: 28890946
[TBL] [Abstract][Full Text] [Related]
19. Genetic interactions reveal distinct biological and therapeutic implications in breast cancer.
Lin CJ; Jin X; Ma D; Chen C; Ou-Yang Y; Pei YC; Zhou CZ; Qu FL; Wang YJ; Liu CL; Fan L; Hu X; Shao ZM; Jiang YZ
Cancer Cell; 2024 Apr; 42(4):701-719.e12. PubMed ID: 38593782
[TBL] [Abstract][Full Text] [Related]
20. Genotype-to-Phenotype Associations in the Aggressive Variant Prostate Cancer Molecular Profile (AVPC-m) Components.
Soundararajan R; Viscuse P; Pilie P; Liu J; Logotheti S; Laberiano Fernández C; Lorenzini D; Hoang A; Lu W; Soto LMS; Wistuba II; Xu M; Song X; Shepherd PDA; Navone NM; Tidwell RSS; Lozano G; Logothetis C; Zhang J; Long JP; Estecio MR; Tzelepi V; Aparicio AM
Cancers (Basel); 2022 Jun; 14(13):. PubMed ID: 35805010
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
